Amyloidosis & Kidney Disease
On this page:
- What is amyloidosis?
- What are the kidneys and what do they do?
- What types of amyloidosis affect the kidneys?
- What are the signs and symptoms of primary amyloidosis of the kidneys?
- What are the symptoms of dialysis-related amyloidosis?
- How is primary amyloidosis of the kidneys diagnosed?
- How is dialysis-related amyloidosis diagnosed?
- How is primary amyloidosis of the kidneys treated?
- How is dialysis-related amyloidosis treated?
- Eating, Diet, and Nutrition
- Clinical Trials
What is amyloidosis?
Amyloidosis is a rare disease that occurs when amyloid proteins are deposited in tissues and organs. Amyloid proteins are abnormal proteins that the body cannot break down and recycle, as it does with normal proteins. When amyloid proteins clump together, they form amyloid deposits. The buildup of these deposits damages a person’s organs and tissues. Amyloidosis can affect different organs and tissues in different people and can affect more than one organ at the same time. Amyloidosis most frequently affects the kidneys, heart, nervous system, liver, and digestive tract. The symptoms and severity of amyloidosis depend on the organs and tissues affected.
What are the kidneys and what do they do?
The kidneys are two bean-shaped organs, each about the size of a fist. They are located just below the rib cage, one on each side of the spine. Every day, the two kidneys filter about 120 to 150 quarts of blood to produce about 1 to 2 quarts of urine, composed of wastes and extra fluid. The urine flows from the kidneys to the bladder through tubes called ureters. The bladder stores urine. When the bladder empties, urine flows out of the body through a tube called the urethra, located at the bottom of the bladder. In men, the urethra is long, while in women it is short.
What types of amyloidosis affect the kidneys?
Primary amyloidosis and dialysis-related amyloidosis are the types of amyloidosis that can affect the kidneys.
Primary Amyloidosis of the Kidneys
The kidneys are the organs most commonly affected by primary amyloidosis. Amyloid deposits damage the kidneys and make it harder for them to filter wastes and break down proteins. When the kidneys become too damaged, they may no longer be able to function well enough to maintain health, resulting in kidney failure. Kidney failure can lead to problems such as high blood pressure, bone disease, and anemia—a condition in which the body has fewer red blood cells than normal.
People who suffer from kidney failure and have been on long-term dialysis may develop dialysis-related amyloidosis. This type of amyloidosis occurs when a certain protein, called beta-2 microglobulin, builds up in the blood because dialysis does not remove it completely. The two types of dialysis are
- hemodialysis. Hemodialysis uses a special filter called a dialyzer to remove wastes and extra fluid from the blood.
- peritoneal dialysis. Peritoneal dialysis uses the lining of the abdominal cavity—the space in the body that holds organs such as the stomach, intestines, and liver—to filter the blood.
Dialysis-related amyloidosis is a complication of kidney failure because neither hemodialysis nor peritoneal dialysis effectively filters beta-2 microglobulin from the blood. As a result, elevated amounts of beta-2 microglobulin remain in the blood.
What are the signs and symptoms of primary amyloidosis of the kidneys?
The most common sign of primary amyloidosis of the kidneys is nephrotic syndrome—a collection of signs that indicate kidney damage. The signs of nephrotic syndrome include
- albuminuria—an increased amount of albumin, a protein, in the urine. A person with nephrotic syndrome excretes more than half a teaspoon of albumin per day.
- hyperlipidemia—a condition in which a person’s blood has more-than-normal amounts of fats and cholesterol.
- edema—swelling, typically in a person’s legs, feet, or ankles and less often in the hands or face.
- hypoalbuminemia—a condition in which a person’s blood has less-than-normal amounts of albumin.
Other signs and symptoms of primary amyloidosis may include
- fatigue, or feeling tired
- shortness of breath
- low blood pressure
- numbness, tingling, or a burning sensation in the hands or feet
- weight loss
What are the symptoms of dialysis-related amyloidosis?
The symptoms of dialysis-related amyloidosis may include
- pain, stiffness, and fluid in the joints.
- abnormal, fluid-containing sacs, called cysts, in some bones.
- carpal tunnel syndrome, caused by unusual buildup of amyloid proteins in the wrists. The symptoms of carpal tunnel syndrome include numbness or tingling, sometimes associated with muscle weakness, in the fingers and hands.
Dialysis-related amyloidosis most often affects bones, joints, and the tissues that connect muscle to bone, called tendons. The disease may also affect the digestive tract and organs such as the heart and lungs. Bone cysts caused by dialysis-related amyloidosis can lead to bone fractures. Dialysis-related amyloidosis can also cause tears in tendons and ligaments. Ligaments are tissues that connect bones to other bones.
How is primary amyloidosis of the kidneys diagnosed?
A health care provider diagnoses primary amyloidosis of the kidneys with
- a medical and family history
- a physical exam
- blood tests
- a kidney biopsy
Medical and Family History
Taking a medical and family history may help a health care provider diagnose amyloidosis of the kidneys. He or she will ask the patient to provide a medical and family history.
A physical exam may help diagnose primary amyloidosis of the kidneys. During a physical exam, a health care provider usually
- examines a patient’s body to check for swelling
- uses a stethoscope to listen to the lungs
- taps on specific areas of the patient’s body
A health care provider may use urinalysis—the testing of a urine sample—to check for albumin and amyloid proteins in urine. The patient provides a urine sample in a special container at a health care provider’s office or a commercial facility. A nurse or technician can test the sample in the same location or send it to a lab for analysis. More-than-normal amounts of albumin in urine may indicate kidney damage due to primary amyloidosis. Amyloid proteins in urine may indicate amyloidosis.
The health care provider may use blood tests to see how well the kidneys are working and to check for amyloid proteins and hyperlipidemia. A blood test involves drawing a patient’s blood at a health care provider’s office or a commercial facility and sending the sample to a lab for analysis. Blood tests for kidney function measure the waste products in the blood that healthy kidneys normally filter out. Hyperlipidemia may indicate nephrotic syndrome. Amyloid proteins in blood may indicate amyloidosis.
Only a biopsy can show the amyloid protein deposits in the kidneys. A health care provider may recommend a kidney biopsy if other tests show kidney damage. A kidney biopsy is a procedure that involves taking a piece of kidney tissue for examination with a microscope. A health care provider performs a kidney biopsy in a hospital with light sedation and local anesthetic. The health care provider uses imaging techniques such as ultrasound or a computerized tomography (CT) scan to guide the biopsy needle into the kidney and take the tissue sample. A pathologist—a doctor who specializes in diagnosing diseases––examines the tissue in a lab for amyloid proteins and kidney damage.
The biopsy results can help the health care provider determine the best course of treatment.
How is dialysis-related amyloidosis diagnosed?
A health care provider diagnoses dialysis-related amyloidosis with
- blood tests
- imaging tests
A health care provider can use urinalysis and blood tests to detect the amount of amyloid proteins in urine and blood. Imaging tests, such as x-rays and CT scans, can provide pictures of bone cysts and amyloid deposits in bones, joints, tendons, and ligaments. An x-ray technician performs imaging tests in a health care provider’s office, an outpatient center, or a hospital. A radiologist—a doctor who specializes in medical imaging—interprets the images. A patient does not require anesthesia.
How is primary amyloidosis of the kidneys treated?
A health care provider treats primary amyloidosis of the kidneys with the following:
- medication therapy, including chemotherapy
- a stem cell transplant
- treating other conditions
Medication therapy. The goal of medication therapy, including chemotherapy, is to reduce amyloid protein levels in the blood. Many health care providers recommend combination medication therapy such as
- melphalan (Alkeran), a type of chemotherapy
- dexamethasone (Decadron), an anti-inflammatory steroid medication
These medications can stop the growth of the cells that make amyloid proteins. These medications may cause hair loss and serious side effects, such as nausea, vomiting, and fatigue.
Stem cell transplant. A stem cell transplant is a procedure that replaces a patient’s damaged stem cells with healthy ones. Stem cells are found in the bone marrow and develop into three types of blood cells the body needs. To prepare for a stem cell transplant, the patient receives high doses of chemotherapy. The actual transplant is like a blood transfusion. The transplanted stem cells travel to the bone marrow to make healthy new blood cells. The chemotherapy a patient receives to prepare for the transplant can have serious side effects, so it is important to talk with the health care provider about the risks of this procedure.
Read more in Blood and Bone Marrow Transplant.
Treating other conditions. Primary amyloidosis has no cure, so treating some of the side effects and other conditions seen with the disease is essential. Other conditions may include
- anemia—treatment may include medications
- depression—treatment may include talking with a mental health counselor and taking medications
- fatigue—treatment may include changes in diet and activity level
- kidney disease—treatment may include medications to help maintain kidney function or slow the progression of kidney disease
A patient and his or her family should talk with the health care provider about resources for support and treatment options.
How is dialysis-related amyloidosis treated?
A health care provider treats dialysis-related amyloidosis with
- medication therapy
- newer, more effective hemodialysis filters
- a kidney transplant
The goal of medication therapy and the use of newer, more effective hemodialysis filters is to reduce amyloid protein levels in the blood. Medication therapy can help reduce symptoms such as pain and inflammation. A health care provider may treat a person with dialysis-related amyloidosis who has bone, joint, and tendon problems, such as bone cysts and carpal tunnel syndrome, using surgery.
Dialysis-related amyloidosis has no cure; however, a successful kidney transplant may stop the disease from progressing.
Eating, Diet, and Nutrition
Researchers have not found that eating, diet, and nutrition play a role in causing or preventing primary amyloidosis of the kidneys or dialysis-related amyloidosis. People with nephrotic syndrome may make dietary changes such as
- limiting dietary sodium (PDF, 167 KB) , often from salt, to help reduce edema and lower blood pressure
- decreasing liquid intake to help reduce edema and lower blood pressure
- eating a diet low in saturated fat and cholesterol to help control more-than-normal amounts of fats and cholesterol in the blood
Health care providers may recommend that people with kidney disease eat moderate or reduced amounts of protein. Proteins break down into waste products that the kidneys filter from the blood. Eating more protein than the body needs may burden the kidneys and cause kidney function to decline faster. However, protein intake that is too low may lead to malnutrition, a condition that occurs when the body does not get enough nutrients.
People with kidney disease on a restricted protein diet (PDF, 112 KB) should receive blood tests that can show low nutrient levels. People with primary amyloidosis of the kidneys or dialysis-related amyloidosis should talk with a health care provider about dietary restrictions to best manage their individual needs.
Learning as much as you can about your treatment will help make you an important member of your health care team.
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and other components of the National Institutes of Health (NIH) conduct and support research into many diseases and conditions.
What are clinical trials, and are they right for you?
Clinical trials are part of clinical research and at the heart of all medical advances. Clinical trials look at new ways to prevent, detect, or treat disease. Researchers also use clinical trials to look at other aspects of care, such as improving the quality of life for people with chronic illnesses. Find out if clinical trials are right for you.
What clinical trials are open?
Clinical trials that are currently open and are recruiting can be viewed at www.ClinicalTrials.gov.
This content is provided as a service of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health. The NIDDK translates and disseminates research findings through its clearinghouses and education programs to increase knowledge and understanding about health and disease among patients, health professionals, and the public. Content produced by the NIDDK is carefully reviewed by NIDDK scientists and other experts.
The NIDDK would like to thank:
Glenn Chertow, M.D., University of California at San Francisco; William J. Stone, M.D., Vanderbilt University; Morie A. Gertz, M.D., Mayo Clinic